Extended Data Fig. 2: Stage differences in pathway and gene alteration patterns, age and additional clinical features.
a,b, Pathway- (a) and gene-level alteration (b) prevalence by clinical stage at diagnosis. Analysis limited to high-purity tumor samples (n = 1,076) and genes or pathways altered in at least 3 tumors in at least one stage. c, Age at diagnosis across the clinical stages at diagnosis including all patients (left, n = 2,336) and excluding patients with pathogenic germline variants (right, n = 2,006). Boxes represent the 25th, 50th (median) and 75th percentiles. Whiskers represent the minimum and maximum values, no further than 1.5× the interquartile range (IQR) from the respective upper and lower quartiles, with points beyond this range plotted individually. Groups were compared using two-sided Wilcoxon rank sum tests; nominal P value displayed. d, Tumor ___location, tobacco exposure and personal history of pancreatitis, hypertension, cancer, autoimmune disease, coronary artery disease and diabetes by clinical stage at diagnosis (n = 1,480). Error bars represent 95th percentile binomial CIs around the mean for a, b and d. Enrichment was calculated using a two-sided Fisher exact test for a, b and d with nominal P values displayed. P values were adjusted for multiple testing by FDR for assessment of significance for a and b (colored by Padj < 0.05).
